Comparative Pharmacology
Head-to-head clinical analysis: ORLEX versus ORLEX HC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ORLEX versus ORLEX HC.
ORLEX vs ORLEX HC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Orlistat is a reversible inhibitor of gastric and pancreatic lipases, preventing the hydrolysis of dietary triglycerides into absorbable free fatty acids and monoglycerides. This reduces dietary fat absorption by approximately 30%.
Hydrocodone is a full opioid agonist with relative selectivity for mu-opioid receptors, though it can bind to other opioid receptors at higher doses. Its analgesic effects are mediated via modulation of nociceptive pathways in the CNS. Homatropine is an anticholinergic agent that reduces excessive respiratory tract secretions by blocking muscarinic receptors.
Orally, 1-2 tablets (5-10 mg of hydrocodone equivalent) every 4-6 hours as needed for pain; maximum 12 tablets per day.
1 capsule (hydrocortisone 5 mg, phenylephrine 5 mg, chlorpheniramine 4 mg) orally every 4-6 hours as needed, not exceeding 6 capsules per day.
None Documented
None Documented
Terminal elimination half-life: 4-6 hours; in renal impairment, half-life can extend to >12 hours requiring dose adjustment.
Hydrocodone: terminal half-life 3.8-5.6 hours (mean ~4.5 h) in adults; clinically, steady state in ~1-2 days. Homatropine: ~8-12 hours.
Renal: 70% (as unchanged drug and metabolites); Biliary/Fecal: 30%
ORLEX HC contains Hydrocodone and Homatropine. Hydrocodone: primarily renal elimination (~85% as metabolites, ~5% unchanged). Homatropine: biliary/fecal (up to 70%) and renal (30%).
Category C
Category C
Muscle relaxant
Muscle relaxant/opioid combination